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Background: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell proliferative
disease. In this study, we examined the treatment outcomes and role of radiotherapy in the management of
POEMS syndrome.
Methods: In total, 33 patients diagnosed with POEMS syndrome were analyzed. These patients presented with
osteosclerotic myeloma (OSM, n = 13), Castleman’s disease (CD, n = 4), OSM with CD (n = 10), and vascular
endothelial growth factor elevation without gross lesions (VEGFe, n = 6), respectively. The patients were treated
by radiotherapy alone (n = 4), chemotherapy alone (n = 16), or a combination thereof (n = 9).
Results: The clinical response rates of radiotherapy, chemotherapy, and radiotherapy plus chemotherapy were 75%,
69%, and 89%, respectively. In addition, the hematologic response rates were 50%, 69%, and 71%, respectively.
Among the six patients with limited multiple lesions who underwent radiotherapy, the clinical symptoms were
improved in five patients after radiotherapy. The median progression-free survival (PFS) was 51 months, and the
median overall survival (OS) was 65 months. In univariate analysis, the administration of chemotherapy was
significantly associated with better PFS (p = 0.007) and OS (p = 0.020). In contrast, underlying VEGFe was a
significant factor worsening PFS (p = 0.035) and OS (p = 0.008).
Conclusions: Radiotherapy produces a reliable clinical response and is effective in improving POEMS-associated
symptoms that are refractory to chemotherapy in selected patients with clustered or limited multiple lesions that
can be covered by single radiation field.
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The term POEMS is derived from the primary features
of the disease: polyneuropathy, organomegaly, endocri-
nopathy, M protein, and skin changes [1]. POEMS syn-
drome is a paraneoplastic syndrome caused by an
underlying plasma cell disorders such as osteosclerotic
myeloma (OSM) or Castleman’s disease (CD) [2,3]. Poly-
neuropathy is a typical symptom of this syndrome, and
can be fatal if it is not improved with treatments [4-6].
Other important clinical features, which are not in-
cluded in the POEMS acronym, include papilledema,
thrombocytosis/erythrocytosis, elevated vascular endo-
thelial growth factor (VEGF) levels, and extravascular
volume overload such as peripheral edema, ascites,* Correspondence: jjhmd@yuhs.ac
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unless otherwise stated.pleural effusion, and pericardial effusion [6-9]. Since
there is no single diagnostic test for the diagnosis of
POEMS syndrome, the diagnosis is typically based on
the presence of polyneuropathy associated with mono-
clonal plasma cell disorders presenting with the distinct
symptoms described above. Currently, the Mayo Clinic
POEMS diagnostic criteria are generally accepted and
widely used [3,6,10].
Previous studies have shown that radiotherapy and
chemotherapy are effective treatments for solitary and
multiple lesions, respectively [10-13]. Sometimes, sur-
gery can be an option for patients with cranial vault
plasmacytoma [14]. However, the role of radiotherapy in
patients with multiple lesions remains unclear, and the
treatment outcomes vary according to the underlying
plasma cell disorders [15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatments, including radiotherapy, chemotherapy, or
combined treatment on the symptoms and disease con-
trol in patients with POEMS syndrome.
Methods
Patients
We retrospectively reviewed the medical records of 33
patients who met diagnostic criteria for POEMS syn-
drome, as proposed by the Mayo clinic [7] and treated atTable 1 Patient clinicodemographic characteristics and labora
Characteristic All (n = 33)
No. of patients (%)








Number of POEMS features
≤7 features 19 (58)




IgG and IgA 3 (9)
Type of plasma cell-proliferative disorder
OSM 13 (39)
CD 4 (12)
OSM + CD 10 (30)
VEGF elevation without gross lesion 6 (18)
Plasma cell component in bone marrow
≤5% 20 (61)
>5% 13 (39)




ESR >20 mm/h 16 (48)
Hemoglobin <11 g/dL 2 (6)
Hemoglobin >16 g/dL 5 (15)
Platelets >450 x 103/μL 11 (33)
Creatinine clearance <60 mL/min 5 (15)
RT, radiotherapy; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin;
endothelial growth factor; ESR, erythrocyte sedimentation rate.
*The p value was calculated by the Pearson’s Chi-squared test between RT and nonthe Yonsei University Health System in Seoul, Korea, in
the period between March of 2000 and February of
2013. Patients were diagnosed with POEMS syndrome if
they met the two mandatory major criteria (polyneurop-
athy and monoclonal plasma cell-proliferative disorder),
at least one of the other major criteria (CD, sclerotic
bone lesion, and VEGF elevation), and at least one of
the minor criteria (organomegaly, extravascular volume
overload, endocrinopathy, skin changes, papilledema, and
thrombocytosis/polycythemia). Plasma cell-proliferativetory findings
RT (n = 13) Non-RT (n = 20)
No. of patients (%) No. of patients (%) p value*
51 (25–68) 45 (28–63) 0.592
12 (92) 12 (60) 0.056
1 (8) 8 (40)
2 (15) 4 (20) 0.451
6 (46) 5 (25)
5 (39) 11 (55)
7 (54) 12 (60) 1.000
6 (46) 8 (40)
8 (62) 9 (45) 0.305
5 (38) 8 (40)
0 (0) 3 (15)
8 (62) 5 (25) 0.067
0 (0) 4 (20) 0.136
5 (38) 5 (25) 0.461
0 (0) 6 (30) 0.060
8 (62) 12 (60) 1.000
5 (38) 8 (40)
13 (100) 15 (75) 0.131
0 (0) 5 (25)
5 (38) 11 (55) 1.000
0 (0) 2 (10) 0.508
4 (31) 1 (5) 0.066
2 (15) 9 (45) 0.128
0 (0) 5 (25) 0.131
OSM, osteosclerotic myeloma; CD, Castleman’s disease; VEGF, vascular
-RT.
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OSM with CD, and VEGF elevation without gross lesions.
All patients underwent pretreatment evaluation including
a complete blood cell count (CBC), blood chemistry ana-
lysis, serum and urine electrophoresis and immunofixation
to detect M-protein, whole body bone scan (WBBS), posi-
tron emission tomography/computed tomography, and
bone marrow biopsies from the bilateral iliac bones; in
patients treated after 2007, the serum VEGF levels were
measured. To identify the gross aggregation of plasma
cells in the bone marrow, immunohistochemistry for
syndecan-1 (CD138) was performed.Table 2 POEMS features of the study patients
Characteristic All (n = 33)
No. of patients (%)
Polyneuropathy
Peripheral neuropathy 33 (100)






Diabetes mellitus 6 (18)
Hypothyroidism 15 (45)
Gonadal axis abnormality 10 (30)








Peripheral edema 19 (58)
Ascites 12 (36)
Pleural effusion 13 (39)
Pericardial effusion 7 (21)








RT, radiotherapy; CSF, cerebrospinal fluid; N/A, not applicable.
*The p value was calculated by the Pearson’s Chi-squared test between RT and nonThe study was approved by the Institutional Review
Board of the Yonsei University Health System.
Follow-up
The treatment responses were evaluated on the basis of
several outcomes, including subjective symptom improve-
ments reported by the patients or treating physicians, and
physical examination findings. Furthermore, a nerve con-
duction velocity test, serum immunoglobulin (Ig)A/G/M,
lambda/kappa chain, and imaging studies were also per-
formed to evaluate the treatment responses. Clinical re-
sponses were evaluated by assessing improvements inRT (n = 13) Non-RT (n = 20) p
value*No. of patients (%) No. of patients (%)
13 (100) 20 (100) N/A
5/5 (100) 13/15 (87) 1.00
6 (46) 10 (50) 1.000
7 (54) 11 (55) 0.614
5 (38) 10 (50) 0.722
3 (23) 3 (15) 0.659
3 (23) 12 (60) 0.072
3 (23) 7 (35) 0.701
5 (38) 3 (15) 0.213
0 (0) 0 (0) N/A
11 (85) 14 (70) 0.431
0 (0) 1 (5) 1.000
0 (0) 0 (0) N/A
6 (46) 10 (50) 1.000
6 (46) 13 (65) 0.472
1 (8) 11 (55) 0.009
1 (8) 12 (60) 0.004
0 (0) 7 (35) 0.027
2 (15) 2 (10) 0.488
7 (54) 7 (35)
4 (31) 1 (5)
0 (0) 10 (50) 0.008
7 (54) 4 (20)








Spine 6 (46) N/A N/A
Pelvic bone 5 (38) N/A N/A
Lymph nodes 2 (15) N/A N/A
No. of irradiated bone lesions
Single 7 (54) 1 1
Multiple 6 (46) 4 2-6
Total dose, Gy 13 (100) 45 30-50
Fraction size, Gy 13 (100) 2 1.8-3
Chemotherapy 25 (100)
Melphalan and prednisolone 4 (16) N/A N/A
Vincristine, doxorubicin, and
dexamethasone
2 (8) N/A N/A
High-dose chemotherapy with APBSCT 15 (60) N/A N/A
Others 4 (16) N/A N/A
N/A, non applicable; APBSCT, autologous peripheral blood stem
cell transplantation.
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polyneuropathy, skin changes, pulmonary edema, and
extravascular volume overload. Clinical response was cate-
gorized as improved, mixed, stable, or progressed according
to previous study [12], and only the patients who experi-
enced clinical symptom improvement were considered as
responder. Hematologic responses were defined using the
criteria from a previous study [11]: complete hematologic
response (CRH), no abnormal plasma cell aggregation in
the bone marrow and negative immunofixation in the
serum and urine; very good partial response (VGPRH), a
90% reduction in the M-protein levels or positive immuno-
fixation, as long as M-protein level was at least 0.5 g/dL at
baseline; and partial hematologic response (PRH), a 50% re-
duction in serum M-protein levels. Other cases were de-
fined as no hematologic response (NRH). Follow-up
monitoring included CBC, blood chemistry analyses, serum
and urine assays to detect M-protein, and imaging studies
of the treated areas. Progression was defined as any event
as follows; increase in the M-component in the serum or
urine, aggravation of symptoms associated with POEMS
syndromes, or progression of disease observed upon im-
aging studies.
Statistical analysis
Progression-free survival (PFS) and overall survival (OS)
were quantified from the date of diagnosis to the event
of interest. Statistical analyses were conducted using SPSS
version 20 (SPSS Inc., Chicago, IL). A p value <0.05 was
considered statistically significant. Differences in clinical
features and response rates between patient groups were
analyzed using the Pearson's Chi-squared test. Patient
survival was evaluated using Kaplan-Meier survival curves,
and the log-rank test was used to compare survival rates
between groups. Prognostic factors for survival were ana-
lyzed by univariate analyses using the log-rank test.
Results
Patient characteristics
The clinical and laboratory characteristics of the patients
at the time of diagnosis are summarized in Table 1. All
patients presented with a sensorimotor polyneuropathy
in nerve conduction test. Sixteen (48%) patients had a
poor performance status of Eastern Cooperative Oncology
Group performance score (3), owing to the presence of
peripheral polyneuropathy. All patients presented with
more than four features included in the Mayo Clinic diag-
nostic criteria, and 42% of patients presented with more
than seven features. Thirty (91%), one (3%), and two (6%)
patients presented with lambda, kappa, and both light
chains, respectively. The median frequency of plasma cells
in the bone marrow was 3% (range, 0-18%).
The features of POEMS syndrome according to the ad-
ministration of radiotherapy are summarized in Table 2.Peripheral polyneuropathy, one of the major diagnostic
criteria, was observed in all patients. All patients presented
with polyneuropathy in the lower extremities, and 10 pa-
tients also had polyneuropathy in the upper extremities.
For the 10 patients with polyneuropathy in both the upper
and lower extremities, the symptoms had presented in the
lower extremities first. Elevated protein levels in the
cerebrospinal fluid were observed in 18 patients among 20
patients with available data (90%). The frequencies of extra-
vascular volume overload including ascites (p = 0.009), and
pleural effusion (p = 0.004) and pericardial effusion
(p = 0.027) were significantly lower in patients who
underwent radiotherapy. The frequency of patients
presenting bone lesions was significantly higher in pa-
tients treated with radiotherapy compared to all other
patients (100% versus 50%, p = 0.008).
Radiotherapy was administered to 13 patients (39%)
presenting with OSM with or without CD, and non of
these patients presented with abnormal clonal plasma cells
in the bone marrow. Almost patients (n = 10) treated with
radiation doses of 40 Gy or more. Twenty-five patients
(76%) were treated with chemotherapy. Four patients
did not undergo definitive radiotherapy or chemother-
apy due to low performance status or patients’ refusal;
three of these patients were instead treated with pred-
nisolone or dexamethasone alone, while one patient
received prednisolone and intravenous immunoglobu-
lin. Nine patients received both radiotherapy and
chemotherapy. Detailed treatment features are sum-
marized in Table 3.
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The various treatments and the responses according to
the underlying disease are summarized in Figure 1.
Among the 23 patients presenting with OSM (with or
without CD), six and 14 patients were initially treated
with radiotherapy and chemotherapy, respectively. The
proportions of patients showing improved clinical symp-
toms after the initial treatment were 67% and 50% in the
radiotherapy and chemotherapy groups, respectively.
Out of the 14 patients who initially received chemother-
apy, seven patients subsequently received radiotherapy
due to poor clinical responses to chemotherapy alone.Figure 1 Clinical and hematologic responses of initial and salvage tre
syndrome. OSM, osteosclerotic myeloma; CD, Castleman’s disease; VEGFe,
immunoglobulin; CRR, clinical response rate; HRR, hematologic response ra
chemotherapy. ⁑M-protein persisted after chemotherapy. §In these patients
by chemotherapy.Among these patients, three patients presented with a
single bone lesion, whereas four patients had multiple
bone lesions more than three. After salvage radiotherapy,
six of these seven patients showed clinical response.
Six patients with multiple lesions underwent radiotherapy
due to poor performance status deemed inadequate for
chemotherapy (n = 2), and poor clinical symptom response
after chemotherapy (n = 4). Out of these six patients, the
clinical symptoms were improved in five patients after
radiotherapy, although the serum M-protein levels were re-
duced in only one patient by radiotherapy. The 10 patients
with CD or VEGF elevation without gross lesions wereatments according to underlying disease types of POEMS
vascular endothelial growth factor elevation without gross lesion; Ig,
te. *In these patients, the clinical symptoms were not improved by
, the clinical symptoms and hematologic status were not improved
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munoglobulin (n = 1).
Overall, 23 patients (70%) showed improved clinical
symptoms after treatments. The clinical response rates
for the patients treated with radiotherapy alone, chemo-
therapy alone, and chemoradiotherapy were 75%, 69%,
and 89%, respectively, and these were not statistically
different according to the treatments (p = 0.528). In
addition, two (50%), 11 (69%), and six patients (67%)
showed hematologic response after radiotherapy alone,
chemotherapy alone, and chemoradiotherapy, respect-
ively. No significant differences were observed between
the treatment groups in hematologic response rate
(p = 0.777). OSM patients with or without CD showed
better clinical and hematologic responses compared with
patients with CD only or VEGF elevation without gross
lesions (Table 4).Survivals and prognostic factors
The median follow-up was 40 months for the surviving
patients. The median PFS for all patients was 51 months
with the 5-year PFS rate being 43% (Figure 2A). The
5-year PFS rate was better in patients treated with
chemoradiotherapy (76%) compared to patients treated
with radiotherapy alone (33%) or chemotherapy alone
(28%). However, this result was not statistically signifi-
cant (p = 0.324). The median OS for all patients was
65 months, with the 5-year OS rate being 57% (Figure 2B).
The 5-year OS rate was worse in patients treated
with radiotherapy alone (25%) than patients treated with
chemotherapy alone (68%) or chemoradiotherapy (69%).
This result did not reach statistic significance (p = 0.094).
During the follow-up period, 13 patients died, including
two, five, four, one, and one from treatment-related causes
after chemotherapy, renal failure, pneumonia, coronary
artery occlusive disease, and cerebral hemorrhage after




No. of patients (%)
Improved Mixed Stable
RT 4 3 (75) 0 (0) 1 (25)
CHT 16 11 (69) 1 (6) 2 (13)
RT + CHT 9 8 (89) 0 (0) 0 (0)
Steroid or Ig 4 1 (25) 1 (25) 1 (25)
OSM 13 11 (84) 0 (0) 1 (8)
CD 4 2 (50) 0 (0) 1 (25)
OSM + CD 10 7 (70) 1 (10) 1 (10)
VEGFe 6 3 (50) 1 (17) 1 (17)
Pts, patients; CR, complete response; VGPR, very good partial response; PR, partial r
immunoglobulin; OSM, osteosclerotic myeloma; CD, Castleman’s disease; VEGFe, vasThe results of the univariate analyses for PFS and OS
are shown in Table 5. In the univariate analyses, the use
of chemotherapy was found to be a significant prognostic
factor for PFS (3-year PFS, 71.5% versus 17.5%, p = 0.007)
and OS (3-year OS, 74.1% versus 18.2%, p = 0.020). More-
over, VEGF elevation without gross lesions was found to
be associated with a worse PFS (3-year PFS, 25.0% versus
66%, p = 0.035) and OS (3-year OS, 16.7% versus 74.1%,
p = 0.008) compared with the other subtypes of POEMS
syndrome.Discussion
POEMS syndrome is a rare paraneoplastic syndrome
resulting from underlying plasma cell proliferative dis-
eases including OSM, CD, and VEGF elevation without
gross lesion. Although a large case series of the disease
was reported in the United States over a decade ago [6],
the underlying pathogenesis and optimal treatment for
POEMS syndrome remains unclear, partly due to the
lack of randomized trials on the topic [7,16]. The results
of the present study suggest that local radiotherapy
could achieve durable clinical and hematologic responses
in selected patients.
Osteosclerotic myeloma is characterized by osteosclero-
tic bone lesions caused by plasmacytoma or associated
with POEMS syndrome. On the other hand, multiple mye-
loma is typically associated with osteolytic bone lesions
[17], while bone lesions in cases of polyneuropathy are
often osteosclerotic or mixed osteosclerotic and osteolytic
[5,6]. Several studies have shown that OSM with a low
burden of clonal plasma cells can be effectively treated
with local radiotherapy [5,6,12,18-21]. Accordingly, in our
study, we found that radiotherapy or radiotherapy plus
chemotherapy produced a good clinical response of 89%
and a hematologic response of 67%. Although the optimal
dose of radiation for OSM has not been thoroughly
investigated, moderate doses of over 40 Gy may bey and type of plasma cell-proliferative disorder
Hematologic response
No. of patients (%)
Progression CRH VGPRH PRH NRH
0 (0) 1 (25) 1 (25) 0 (0) 2 (50)
2 (13) 5 (31) 2 (13) 4 (25) 5 (31)
1 (11) 4 (44) 1 (11) 1 (11) 3 (33)
1 (25) 0 (0) 0 (0) 0 (0) 4 (100)
1 (8) 6 (46) 1 (8) 3 (23) 3 (23)
1 (25) 0 (0) 1 (25) 2 (50) 1 (25)
1 (10) 3 (30) 2 (20) 0 (0) 5 (50)
1 (17) 1 (17) 0 (0) 0 (0) 5 (83)
esponse; NR, no response; RT, radiotherapy; CHT, chemotherapy; Ig,
cular endothelial growth factor elevation without growth lesion.
Figure 2 Kaplan-Meier plot of (A) progression-free survival and (B) overall survival for all patients (n = 33), and patients treated with
radiotherapy alone (n = 4), chemotherapy alone (n = 16), and chemoradiotherapy (n = 9). RT, radiotherapy; CHT, chemotherapy.
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[12,22]. In the present study, only three patients re-
ceived radiation doses less than 40 Gy, and among
these three patients, one patient experienced disease
progression. In addition, the two patients who did not
respond to initial radiotherapy received 42 Gy and
50 Gy of radiotherapy. These doses were similar to those
administered to the patients who responded to treatment,
and were hence considered sufficient; therefore, the doses
of radiation may not be responsible for the poor clinical
responses, when radiation over 40 Gy was given.
Since disease multiplicity is associated with a higher
risk of systemic involvement and a high burden of clonal
plasma cells, it represents a very important factor to take
into account for the decision of the treatment, especially,
for patients with an underlying OSM. As a result, these
patients are usually treated with chemotherapy, and the
role of radiotherapy is thus uncertain in these patients.Table 5 Univariate prognostic factor analysis
Factor No. of ca
Age >50 years (vs. ≤50 years) 13/20
Radiotherapy (Y/N) 13/20
Chemotherapy (Y/N) 25/8
HD Chemotherapy with ABSCT (vs. SD chemotherapy) 15/10
IgG M-protein subtype (vs. other subtypes) 17/16
VEGF elevation without gross lesion (vs. other subtypes) 6/27
BM plasma cells more than 5% (vs. ≤5%) 13/20
The presence of abnormal clonal plasma cells in BM (Y/N) 5/28
Extravascular volume overload except peripheral edema (Y/N) 16/17
Number of POEMS features >7 (vs. ≤7) 14/19
Multiple bone lesions (vs. single bone lesion) 12/11
PFS, progression free survival; OS, overall survival; ABSCT, autologous peripheral blo
vascular endothelial growth factor; BM, bone marrow.
*Log-rank test.In the present study, six patients with multiple lesions
underwent radiotherapy, and this was found to have ef-
fectively improved the POEMS associated symptoms, al-
though the hematologic response to radiotherapy was
relatively poor in these patients.
Furthermore, in the present study, among the six pa-
tients presenting with VEGF elevation without gross
lesions, five patients were treated with systemic chemo-
therapy, whereas the other one patient received systemic
corticosteroid therapy and intravenous immunoglobulin.
Interestingly, the treatment responses of these patients
were poorer than those of the patients with osteosclero-
tic myeloma (Table 4). Moreover, the PFS and OS rates
were found to be significantly inferior in these patients
compared to those in patients with other subtypes of
underlying disease (Table 5). A French study reported that
six out of 25 POEMS patients did not have bone lesion-
like monoclonal gammopathy of unknown significancese 3-year PFS (%) p value* 3-year OS (%) p value*
53.3/62.4 0.931 56.4/66.0 0.259
64.8/56.7 0.310 66.6/59.4 0.782
71.5/17.5 0.007 74.1/18.2 0.020
80.8/58.3 0.291 78.8/66.7 0.253
54.4/65.6 0.719 61.1/65.8 0.775
25.0/66.0 0.035 16.7/74.1 0.008
61.4/59.5 0.771 60.6/62.5 0.821
60.0/60.8 0.249 80.0/60.4 0.552
49.2/70.0 0.155 53.5/71.1 0.212
46.4/67.7 0.220 45.9/74.2 0.127
62.3/66.3 0.742 77.9/70.7 0.906
od stem cell transplantation; SD, standard dose; Ig, immunoglobulin; VEGF,
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patient among four patients with available data in that
series [5]. The reason for the poor clinical outcomes in
these patients is unclear, and previous studies have re-
ported only a small number of POEMS patients present-
ing with VEGF elevation without gross lesions; therefore,
further investigations regarding these patients is needed.
In the present study, the administration of chemother-
apy significantly improved PFS and OS. Previous studies
have demonstrated that melphalan-based chemotherapy
protocols were able to achieve response rates over 40%
[4,6,15,24]. Moreover, high-dose chemotherapy with
PBSCT has also produced encouraging results, with a 5-
year PFS of 75% [11,13,25,26]. Therefore, the selection
of patients indicated for chemotherapy and the choice of
chemotherapy regimen based on the patients’ underlying
clonal disease are important to improve outcomes.
The present study has some limitations including the
retrospective nature and the relatively small sample size.
Moreover, patients who did not undergo radiotherapy
more frequently presented with adverse events such as
ascites, pleural effusion, or pericardial effusion compared
to patients treated with radiotherapy. Furthermore, among
the 13 patients treated with radiotherapy, nine patients
also underwent chemotherapy; and therefore, there is a
possibility that the effects of radiotherapy may have been
overestimated. However, despite these limitations, radio-
therapy was found to produce good clinical responses in
patients with a solitary lesion and clustered or limited
multiple lesions, and radiotherapy may hence be effective
as a definitive treatment in POEMS patients with localized
OSM or as a palliative treatment to improve clinical symp-
toms in POEMS patients with clustered or limited mul-
tiple lesions.
Conclusions
We here have shown that radiotherapy produced good
clinical and hematologic responses, especially in patients
with an underlying OSM. Additionally, radiotherapy and
chemotherapy appear to both be effective treatments for
underlying plasma cell proliferative diseases. Furthermore,
we also found that patients with POEMS syndrome pre-
senting with VEGF elevation without gross lesions tend to
have a poor prognosis. Further large-scale studies are
needed in the future to improve the understanding of the
underlying disease pathogenesis and to elucidate the ap-
propriate management of this disease based on patient
characteristics.
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